Drug prices and trends for FLUTICASONE ELLIPTA

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
FLUTICASONE ELLIPTA 100 MCG INH	66993-0167-97	4.27493	EACH	2026-06-17
FLUTICASONE ELLIPTA 50 MCG INH	66993-0166-97	4.21904	EACH	2026-06-17
FLUTICASONE ELLIPTA 200 MCG INH	66993-0168-97	5.66988	EACH	2026-06-17
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: May 15, 2026

Fluticasone Ellipta (fluticasone furoate inhalation powder; combination inhaler platform name “Ellipta”) is an established branded inhaled corticosteroid with entrenched payer coverage and limited near-term generic entry risk in most markets. Pricing outcomes over the next 5 to 10 years will be driven by (1) loss of exclusivity and (2) payer-driven net-price compression tied to formulary movement, (3) channel inventory and rebate resets, and (4) competitive substitution within inhaled corticosteroid (ICS) classes and across combination products (ICS/LABA and triple therapy).

What is the current US market structure for Fluticasone Ellipta (fluticasone furoate) and how does pricing typically behave?

Which products sit under “Fluticasone Ellipta” and what are the practical pricing units?

In US commercial channels, “Fluticasone Ellipta” pricing is assessed by strength and device presentation. The key unit economics in payer contracts are based on:

NDC/strength (the inhaled dose strength)
Device (Ellipta dry powder inhaler)
Contract tier placement (preferred vs non-preferred)
Expected utilization (persistence and switching behavior)
Covered indication (asthma vs COPD label scope within the product family)

A critical point for price projection work: net price is rebate-dependent. Wholesale acquisition cost (WAC) can hold up while net price erodes through higher rebates.

What pricing forces dominate for ICS inhalers like fluticasone furoate?

Market pricing for ICS inhalers is shaped by:

Multi-source substitution pressure from other ICS products (including branded and authorized generics where applicable)
Manufacturer rebate strategy (rebate pressure rises when utilization softens)
PBM formulary designs that steer stable patients to “step edits”
Manufacturer-sponsored patient support that reduces payer net cost in practice for some cohorts

How does payer behavior usually change over a patent/generic transition?

As exclusivity weakens:

Formularies often shift from “brand preferred” to “brand non-preferred” before true generic entry.
After generic launch, payers commonly move toward lower-cost therapeutics even if clinical equivalence is not the sole driver.
Net price compression typically occurs before generic competition becomes visible in observed pharmacy claims because contracts reset in anticipation of entry risk.

What patents protect Fluticasone Ellipta and how do they affect exclusivity-driven price stability?

How long does exclusivity typically support brand pricing for fluticasone furoate inhalation?

For branded inhaled drugs, price durability depends on multiple overlapping protections:

Patent coverage on the active ingredient form (polymorph/crystal form, composition)
Device and formulation patents (particle engineering, inhalation performance, dose uniformity)
Method-of-use patents for specific regimens or patient subgroups
Regulatory exclusivities (for FDA brand exclusivity is typically tied to the New Drug Application approval pathway)

If the patent estate remains broad and enforcement is active, branded net price can stay higher longer.

What patent risk categories matter most for price projections?

The largest price-impact categories are:

Composition/formulation patents that block generics and authorized generics.
Method-of-use or dosing regimen patents that can restrict “switch” claims even if the same molecule is available.
Delivery performance patents that can create practical barriers for dry powder inhaler equivalence.
Litigation outcomes that determine whether launch is “at risk” or delayed by a settlement.

When does Fluticasone Ellipta lose exclusivity, and when could generics or “at-risk” launches affect net prices?

Exclusivity timeline logic (how to map timing to pricing)

A typical pricing pattern in inhaled brands:

Pre-loss: net price starts to decline via rebate increases and contract changes.
Patent challenge or litigation: temporary stabilization in WAC but net price can drop.
Generic entry: a step-change downward in net price, then a slower drift driven by persistence and formulary retention.

Price projection sensitivity to “entry timing”

Even a 6 to 12 month difference in entry timing can materially change:

FY revenue recognition due to contract ratchets
patient retention and switching dynamics
PBM “step therapy” rules
inventory pull-through

What Orange Book status and listing patterns matter for generic entry risk?

How Orange Book listings translate to “who can launch what”

Orange Book listings indicate:

Drug substance and drug product patents that are listed for FDA-approved products
Expiration dates and applicable patent types
Whether challenges would be Paragraph IV driven

For price projection, the actionable element is whether the listed patents are:

Expiring soon (late-stage uncertainty)
Still active but vulnerable to enforcement gaps
Covered by multiple patents such that even if one expires, others delay full substitutability

Which companies are likely to challenge Fluticasone Ellipta, and what does that imply for price?

Why challenger identity matters

Challengers usually pick launch timing based on:

Court timelines and settlement probabilities
Ability to launch across strengths
Ability to secure payer acceptance for their NDCs

For brand net price forecasts, the key is not just whether a generic files, but:

whether it wins at the district court stage
whether it settles for a deferred launch date
whether it obtains preferred formulary status quickly

What formulations are protected for Fluticasone Ellipta, and what delivery barriers affect generic substitution?

Dry powder inhaler equivalence: why device performance affects claims

For inhalation powders, substitution friction can occur even when API is the same. Generic development must meet:

aerodynamic particle size distribution targets
dose delivery uniformity standards
device-based resistance and aerosolization performance

If brand delivery performance patents are enforced, generics can face longer timelines or higher settlement value.

What generic entry risks exist for Fluticasone Ellipta and how do they differ across geographies?

US vs ex-US pricing dynamics

US is generally the most sensitive to Paragraph IV and patent litigation timing because:

market access is PBM-contract-driven
generic entry triggers rapid formulary movement
WAC and net price behavior are heavily tied to rebate resets

Outside the US, price often declines more gradually, driven by:

local reimbursement rules
tendering and reference pricing frameworks
biosimilar-like dynamics do not typically apply because this is small molecule inhaled therapy, not biologic

Geography-specific launch patterns

If generics can’t launch the full strength/device catalog, payers may still keep brand on formulary for specific dosing regimens. That slows price erosion.

How does Fluticasone Ellipta compare with competing ICS and ICS/LABA products on pricing and substitution risk?

Competitive set: what typically pressures fluticasone furoate net price

In practice, fluticasone furoate competes with:

other branded ICS inhalers (molecule and device class competition)
ICS/LABA fixed-dose combinations (patient step-down or step-up substitution)
triple therapy where the ICS component is “locked” into the combination product

The most relevant competitive pressure for pricing is combination substitution. When payers push combination therapies, the effective demand for standalone ICS can decline, leading to rebate pressure for the remaining brand-covered cohorts.

Net price vs utilization: what changes after payer switching

Even if unit price declines, the biggest revenue risk can be:

loss of new starts
increased switching among stable patients at renewal cycles
reduced persistence when step edits trigger formulary substitutions

Price projection model: what range of net price declines is reasonable under plausible scenarios?

Scenario framework tied to generic timing

Because exact Orange Book expiration dates and litigation outcomes are not provided here, the projection logic is expressed as scenario deltas rather than point forecasts. Use these deltas as underwriting assumptions for internal models.

Net price decline assumptions (annualized)

Scenario A (late exclusivity or successful enforcement): 2% to 4% annual net price compression, driven by rebate reset and competitive pressure, without step-change from generic entry.
Scenario B (generic threatens but entry delayed): 5% to 8% annual net price compression in years leading to entry risk; potential temporary stabilization after settlement.
Scenario C (generic entry in US across major strengths): 20% to 40% net price step-down in the first 6 to 18 months after meaningful entry, followed by 5% to 10% annual erosion.
Scenario D (partial entry, limited strength/device coverage): 12% to 25% step-down for covered strengths, with mixed outcomes for uncovered strengths; overall erosion likely closer to 7% to 15% annually after uptake.

Revenue exposure sensitivity

Revenue exposure equals:

(covered units) × (net price) × (volume retention factor)

Volume retention can swing faster than price:

If payer formulary moves occur pre-entry, volume can fall even before net price resets.
After generic entry, volume can split rapidly if the payer classifies the generic as preferred.

What does settlement vs litigation mean for Fluticasone Ellipta pricing outcomes?

Settlement-backed entry (less disruption)

Settlements typically:

delay generic launch
reduce uncertainty that forces PBM contract changes
permit the brand to preserve formulary status longer

This often results in smoother net price decline and less abrupt revenue loss.

At-risk or faster-than-expected launch (more disruption)

If a generic launches at risk:

PBMs can accelerate formulary changes immediately
branded net price declines faster due to higher rebate demands
revenue volatility increases, with sharp quarter-to-quarter changes

What FDA and regulatory factors affect commercial launch timing and price?

FDA pathway does not apply the same way as in biologics

For small molecules like fluticasone furoate, the main regulatory timing link to price is:

ANDA approval timing
FDA labeling equivalence and strength-by-strength substitutability

If the generic product labels do not enable identical utilization patterns, payers may retain the brand for certain cohorts.

Key revenue and pricing watch metrics for Fluticasone Ellipta underwriting

Leading indicators (signal before revenue is reported)

Formulary moves (preferred to non-preferred)
PBM rebate contract updates and tiering changes
Pharmacy claim share shifts by strength and NDC
“New-to-brand” scripts trends
Persistency curves (duration on therapy)

Lagging indicators (confirm price erosion)

ASP declines (if publicly tracked)
WAC and net price gap changes
Gross-to-net trend in manufacturer reporting
Settlements or court rulings impacting expected entry dates

Key Takeaways

Fluticasone Ellipta pricing durability is primarily a function of exclusivity strength and enforceability, not WAC alone.
Net price compression typically begins well before generic entry through rebate and formulary tier changes.
If full-strength generic entry occurs in the US, a 20% to 40% net price step-down is a reasonable underwriting range, followed by continued annual erosion.
If entry is partial or delayed, compression is usually smoother, with 2% to 8% annual net declines until a clearer substitution trigger emerges.
The biggest revenue risk can come from volume loss via formulary switching and step-therapy protocols, not only from unit price decline.

FAQs

1. What drives net price erosion for inhaled corticosteroid brands like fluticasone furoate more than WAC?
Rebate rates, PBM tier placement, and contract resets triggered by formulary movement and perceived generic risk.

2. How quickly do payers move after a generic approval for an inhaled small molecule?
Often within the first one to two contract cycles, with accelerated shifts when the generic is preferred and covered across common strengths.

3. Does partial generic entry reduce the overall revenue impact compared with full entry?
Yes. Limited strength/device coverage can leave meaningful brand share protected and typically reduces the step-change magnitude.

4. What competitive class shifts most threaten standalone ICS brands’ volume?
ICS/LABA and triple-therapy substitution through step therapy and guideline-driven regimen selection.

5. What litigation outcome patterns tend to preserve brand pricing better?
Settlements that defer launch and remove at-risk uncertainty usually delay contract repricing and reduce abrupt revenue swings.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Drug Approval Reports and NDA/ANDA Information. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/

Drug Price Trends for FLUTICASONE ELLIPTA

Average Pharmacy Cost for FLUTICASONE ELLIPTA

FLUTICASONE ELLIPTA Market Analysis and Price Projections: Brand Pricing, Generic/Biosimilar Risk, and Post-Exclusivity Revenue Scenarios